134 research outputs found
current clinical practice and available resources
Objective To assess European pediatric rheumatology providers’ current
clinical practices and resources used in the transition from child-centered to
adult-oriented care. Methods European pediatric rheumatologists were invited
to complete a 17-item anonymized e-survey assessing current transition
practices, transition policy awareness, and needs in advance of the
publication of EULAR/PReS recommendations on transition. Results The response
rate was 121/276 (44%), including responses from 115 centers in 22 European
Union countries. Although 32/121 (26%) responded that their centers did not
offer transition services, the majority (99%) agreed that a formalized process
in transitioning patients to adult care is necessary. A minority (<30%) of
respondents stated that they have a written transition policy although 46%
have an informal transition process. Designated staff to support transitional
care were available in a minority of centers: nurse (35%), physiotherapist
(15%), psychologist (15%), social worker (8%), and occupational therapist
(2%). The existence of a designated team member to coordinate transition was
acknowledged in many centers (64% of respondents) although just 36% use a
checklist for young people as part of individualized transitional care.
Conclusion This survey of European pediatric rheumatology providers regarding
transitional care practices demonstrates agreement that transitional care is
important, and wide variation in current provision of transition services
exists
Juvenile arthritis caused by a novel FAMIN (LACC1) mutation in two children with systemic and extended oligoarticular course
Background The pathophysiological origin of juvenile idiopathic arthritis
(JIA) is largely unknown. However, individuals with presumably pathogenic
mutations in FAMIN have been reported, associating this gene with a rare
subtype of this disorder. FAMIN, that is formerly also referred to as LACC1 or
C13orf31, has recently been shown to play a crucial role in immune-metabolic
functions and is involved in regulation of inflammasome activation and
promotion of ROS production. Case presentation We describe two siblings with
severe familial forms of juvenile arthritis in which whole-exome-sequencing
revealed a novel homozygous frameshift mutation (NM_153218.2:c.827delC¸.
p.(T276fs*2) in FAMIN. Conclusions The observation of a new deleterious
mutation adds further evidence that pathogenic mutations in FAMIN are causal
for a monogenic form of JIA. Furthermore the associated phenotype is not
restricted to systemic JIA, but can also be found in other forms of familial
juvenile arthritis
Comparison of treatment response, remission rate and drug adherence in polyarticular juvenile idiopathic arthritis patients treated with etanercept, adalimumab or tocilizumab
Background Treatment response, remission rates and compliance in patients with
polyarticular juvenile idiopathic arthritis (polyJIA) treated with adalimumab,
etanercept, or tocilizumab were analyzed in clinical practice. Methods Data
collected in the German BIKER registry were analyzed in patients with polyJIA
who started treatment with approved biologics, adalimumab, etanercept or
tocilizumab, from 2011 to 2015. Baseline patient characteristics, treatment
response, safety and drug survival were compared. Results Two hundred thirty-
six patient started adalimumab, 419 etanercept and 74 tocilizumab, with
differences in baseline patient characteristics. Baseline Juvenile Disease
Activity Score (JADAS)10 (mean ± SD) in the adalimumab/etanercept/tocilizumab
cohorts was 12.1+/−7.6, 13.8 ± 7.1 and 15.1 ± 7.4, respectively (adalimumab vs
etanercept, p = 0.01), and Childhood Health Assessment Questionnaire
(CHAQ)-disability index scores was 0.43 ± 0.58, 0.59 ± 0.6 and 0.63 ± 0.55,
respectively (adalimumab vs etanercept, p < 0.001). Uveitis history was more
frequent in the adalimumab cohort (OR 5.73; p < 0.001). Balanced patients’
samples were obtained by a generalized propensity score to adjust for baseline
differences. Pediatric ACR30/50/70/90 criterion improvement after 3 months
treatment was achieved by 68%/60%/42%/24% in the etanercept cohort,
67%/59%/43%/27% in the adalimumab cohort and 61%/52%/35%/26% in the
tocilizumab cohort. At 24 months, JADAS minimal disease activity was achieved
in 52.4%/61.3%/52.4% and JADAS remission in 27.9%/34.8%/27.9% patients in the
adalimumab/etanercept/tocilizumab cohorts, respectively. Etanercept was used
in 95.5% of patients as a first biologic, adalimumab in 50.8% and tocilizumab
in 20.2%. There were no important differences in efficacy between first-line
and second-line use of biologics. In total 60.4%/49.4%/31.1% patients
discontinued adalimumab/etanercept/tocilizumab, respectively (HR for
adalimumab 1.67; p < 0.001; HR for tocilizumab 0.35; p = 0.001). Drug survival
rates did not differ significantly in patients on biologic monotherapy
compared with combination therapy with methotrexate. Over 4 years observation
under etanercept/adalimumab/tocilizumab, 996/386/103 adverse events, and
148/119/26 serious adverse events, respectively, were reported. Conclusions In
clinical practice, etanercept is most frequently used as first-line biologic.
Adalimumab/etanercept/tocilizumab showed comparable efficacy toward polyJIA.
Overall, tolerance was acceptable. Interestingly, compliance was highest with
tocilizumab and lowest with adalimumab. This study provides the first
indication for the comparison of different biologic agents in polyarticular
JIA based on observational study data with all their weaknesses and
demonstrates the need for well-controlled head-to-head studies for
confirmation
a comparative study with ultrasonography
Background Valid detection of arthritis is essential in differential diagnosis
of joint pain. Indocyanin green (ICG)-enhanced fluorescence optical imaging
(FOI) is a new imaging method that visualizes inflammation in wrist and finger
joints. Objectives of this study were to compare FOI with ultrasonography (US,
by gray-scale (GS) and power Doppler (PD)) and clinical examination (CE) and
to estimate the predictive power of FOI for discrimination between
inflammatory and non-inflammatory juvenile joint diseases. Methods FOI and
GSUS/PDUS were performed in both hands of 76 patients with joint pain (53 with
juvenile idiopathic arthritis (JIA), 23 with non-inflammatory joint diseases).
Inflammation was graded by a semiquantitative score (grades 0–3) for each
imaging method. Joints were defined clinically active if swollen or tender
with limited range of motion. Sensitivity and specificity of FOI in three
phases dependent on ICG enhancement (P1–P3) were analyzed with CE and
GSUS/PDUS as reference. Results For JIA patients, FOI had an overall
sensitivity of 67.3%/72.0% and a specificity of 65.0%/58.8% with GSUS/PDUS as
reference; specificity was highest in P3 (GSUS 94.3%/PDUS 91.7%). FOI was more
sensitive for detecting clinically active joints than GSUS/PDUS (75.2% vs
57.3%/32.5%). In patients with non-inflammatory joint diseases both FOI and US
showed positive (i.e., pathological) findings (25% and 14% of joints). The
predictive value for discrimination between inflammatory and non-inflammatory
joint diseases was 0.79 for FOI and 0.80/0.85 for GSUS/PDUS. Conclusions
Dependent on the phase evaluated, FOI had moderate to good agreement with CE
and US. Both imaging methods revealed limitations and should be interpreted
cautiously. FOI may provide an additional diagnostic method in pediatric
rheumatology. Trial registration Deutsches Register Klinischer Studien
DRKS00012572. Registered 31 July 2017
The German version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR)
The Juvenile Arthritis Multidimensional Assessment Report (JAMAR) is a new parent/patient reported outcome measure that enables a thorough assessment of the disease status in children with juvenile idiopathic arthritis (JIA). We report the results of the cross-cultural adaptation and validation of the parent and patient versions of the JAMAR in the German language. The reading comprehension of the questionnaire was tested in 10 JIA parents and patients. The participating centres were asked to collect demographic and clinical data along the JAMAR questionnaire in 100 consecutive JIA patients or all consecutive patients seen in a 6-month period and to administer the JAMAR to 100 healthy children and their parents. The statistical validation phase explored descriptive statistics and the psychometric issues of the JAMAR: the three Likert assumptions, floor/ceiling effects, internal consistency, Cronbach\u2019s alpha, interscale correlations, test\u2013retest reliability, and construct validity (convergent and discriminant validity). A total of 319 JIA patients (2.8% systemic, 36.7% oligoarticular, 23.5% RF negative polyarthritis, and 37% other categories) and 100 healthy children were enrolled in eight centres. The JAMAR components discriminated well healthy subjects from JIA patients. All JAMAR components revealed good psychometric performances. In conclusion, the German version of the JAMAR is a valid tool for the assessment of children with JIA and is suitable for use both in routine clinical practice and in clinical research
Therapeutic approaches to pediatric COVID-19: an online survey of pediatric rheumatologists
Data on therapy of COVID-19 in immunocompetent and immunosuppressed children are scarce. We aimed to explore management strategies of pediatric rheumatologists. All subscribers to international Pediatric Rheumatology Bulletin Board were invited to take part in an online survey on therapeutic approaches to COVID-19 in healthy children and children with autoimmune/inflammatory diseases (AID). Off-label therapies would be considered by 90.3% of the 93 participating respondents. In stable patients with COVID-19 on oxygen supply (stage I), use of remdesivir (48.3%), azithromycin (26.6%), oral corticosteroids (25.4%) and/or hydroxychloroquine (21.9%) would be recommended. In case of early signs of 'cytokine storm' (stage II) or in critically ill patients (stage III) (a) anakinra (79.5% stage II; 83.6% stage III) or tocilizumab (58.0% and 87.0%, respectively); (b) corticosteroids (oral 67.2% stage II, intravenously 81.7% stage III); (c) intravenous immunoglobulins (both stages 56.5%); or (d) remdesivir (both stages 46.7%) were considered. In AID, &gt; 94.2% of the respondents would not support a preventive adaptation of the immunomodulating therapy. In case of mild COVID-19, more than 50% of the respondents would continue pre-existing treatment with immunoglobulins (100%), hydroxychloroquine (94.2%), anakinra (79.2%) or canakinumab (72.5%), or tocilizumab (69.8%). Long-term corticosteroids would be reduced by 26.9% (&lt; = 2 mg/kg/d) and 50.0% (&gt; 2 mg/kg/day), respectively, with only 5.8% of respondents voting to discontinue the therapy. Conversely, more than 75% of respondents would refrain from administering cyclophosphamide and anti-CD20-antibodies. As evidence on management of pediatric COVID-19 is incomplete, continuous and critical expert opinion and knowledge exchange is helpful
Proposal for a definition for response to treatment, inactive disease and damage for JIA associated uveitis based on the validation of a uveitis related JIA outcome measures from the Multinational Interdisciplinary Working Group for Uveitis in Childhood (MIWGUC)
Correction: PEDIATRIC RHEUMATOLOGY Volume: 18 Issue: 1 Article Number: 14 DOI: 10.1186/s12969-019-0396-4Background JIA-associated uveitis (JIAU) is a serious, sight-threatening disease with significant long-term complications and risk of blindness, even with improved contemporary treatments. The MIWGUC was set up in order to propose specific JIAU activity and response items and to validate their applicability for clinical outcome studies. Methods The group consists of 8 paediatric rheumatologists and 7 ophthalmologists. A consensus meeting took place on November 2015 in Barcelona (Spain) with the objective of validating the previously proposed measures. The validation process was based on the results of a prospective open, international, multi-centre, cohort study designed to validate the outcome measures proposed by the initial MIWGUC group meeting in 2012. The meeting used the same Delphi and nominal group technique as previously described in the first paper from the MIWGUC group (Arthritis Care Res 64:1365-72, 2012). Patients were included with a diagnosis of JIA, aged less than 18 years, and with active uveitis or an uveitis flare which required treatment with a disease-modifying anti-rheumatic drug. The proposed outcome measures for uveitis were collected by an ophthalmologist and for arthritis by a paediatric rheumatologist. Patient reported outcome measures were also measured. Results A total of 82 patients were enrolled into the validation cohort. Fifty four percent (n = 44) had persistent oligoarthritis followed by rheumatoid factor negative polyarthritis (n = 15, 18%). The mean uveitis disease duration was 3.3 years (SD 3.0). Bilateral eye involvement was reported in 65 (79.3%) patients. The main findings are that the most significant changes, from baseline to 6 months, are found in the AC activity measures of cells and flare. These measures correlate with the presence of pre-existing structural complications and this has implications for the reporting of trials using a single measure as a primary outcome. We also found that visual analogue scales of disease activity showed significant change when reported by the ophthalmologist, rheumatologist and families. The measures formed three relatively distinct groups. The first group of measures comprised uveitis activity, ocular damage and the ophthalmologists' VAS. The second comprised patient reported outcomes including disruption to school attendance. The third group consisted of the rheumatologists' VAS and the joint score. Conclusions We propose distinctive and clinically significant measures of disease activity, severity and damage for JIAU. This effort is the initial step for developing a comprehensive outcome measures for JIAU, which incorporates the perspectives of rheumatologists, ophthalmologists, patients and families.Peer reviewe
Long‐term safety, efficacy, and quality of life in patients with juvenile idiopathic arthritis treated with intravenous abatacept for up to seven years
ClinicalTrials.gov identifier: NCT00095173[Abstract] Objective. The efficacy and safety of abatacept in patients with juvenile idiopathic arthritis (JIA) who experienced an inadequate response to disease‐modifying antirheumatic drugs were previously established in a phase III study that included a 4‐month open‐label lead‐in period, a 6‐month double‐blind withdrawal period, and a long‐term extension (LTE) phase. The aim of this study was to present the safety, efficacy, and patient‐reported outcomes of abatacept treatment (10 mg/kg every 4 weeks) during the LTE phase, for up to 7 years of followup.
Methods. Patients enrolled in the phase III trial could enter the open‐label LTE phase if they had not achieved a response to treatment at month 4 or if they had received abatacept or placebo during the double‐blind period.
Results. One hundred fifty‐three (80.5%) of 190 patients entered the LTE phase, and 69 patients (36.3%) completed it. The overall incidence rate (events per 100 patient‐years) of adverse events decreased during the LTE phase (433.61 events during the short‐term phase [combined lead‐in and double‐blind periods] versus 132.39 events during the LTE phase). Similar results were observed for serious adverse events (6.82 versus 5.60), serious infections (1.13 versus 1.72), malignancies (1.12 versus 0), and autoimmune events (2.26 versus 1.18). American College of Rheumatology (ACR) Pediatric 30 (Pedi 30) responses, Pedi 70 responses, and clinically inactive disease status were maintained throughout the LTE phase in patients who continued to receive therapy. Improvements in the Child Health Questionnaire physical and psychosocial summary scores were maintained over time.
Conclusion. Long‐term abatacept treatment for up to 7 years was associated with consistent safety, sustained efficacy, and quality‐of‐life benefits in patients with JIA
Application and performance of disease activity indices proposed for patients with systemic sclerosis in an international cohort of patients with juvenile systemic sclerosis
Funding Information: The author(s) disclosed receipt of the following financial support for the research, authorship and/or publication of this article: the inception cohort project is supported by an unrestricted grant from the Joachim Herz Stiftung, Hamburg, Germany. Publisher Copyright: © The Author(s) 2023.Objectives: Juvenile systemic sclerosis is a rare childhood disease. Three disease activity indices have been published for adult patients with systemic sclerosis: the European Scleroderma Study Group Index, a modified version of the European Scleroderma Study Group Index and the revised European Scleroderma Trials and Research index. The objective of this study was to determine the feasibility and performance of the three disease activity indices in a prospectively followed cohort of patients with juvenile systemic sclerosis. Methods: The analysis cohort was selected from the prospective international inception cohort enrolling juvenile systemic sclerosis patients. The correlation of the disease activity indices with the physicians’ and the patients’ global assessment of disease activity was determined. The disease activity indices were compared between patients with active and inactive disease. Sensitivity to change between 6- and 12-month follow-up was investigated by mixed models. Results: Eighty percent of the 70 patients had a diffuse cutaneous subtype. The revised European Scleroderma Trials and Research index was highly correlated with the physician-reported global disease activity/parents-reported global disease activity (r = 0.74/0.64), followed by the European Scleroderma Study Group activity index (r = 0.61/0.55) and the modified version of the European Scleroderma Study Group activity index (r = 0.51/0.43). The disease activity indices significantly differed between active and inactive patients. The disease activity indices showed sensitivity to change between 6- and 12-month follow-up among patients who improved or worsened according to the physician-reported global disease activity and the parents-reported global disease activity. Conclusion: Overall, no disease activity score is superior to the other, and all three scores have limitations in the application in juvenile systemic sclerosis patients. Furthermore, research on the concept of disease activity and suitable scores to measure disease activity in patients with juvenile systemic sclerosis is necessary in future.Peer reviewe
- …